Standard Biotools vs Personalis
Standard Biotools reported revenue of $85 million in fiscal 2025, 1.2 times Personalis' $70 million in fiscal 2025. Standard Biotools' revenue fell 6.2% in its latest year, and Personalis' fell 17.7%. Standard Biotools had an operating margin of -129.2%, against -126.4% at Personalis. Free cash flow was −$83 million at Standard Biotools and −$79 million at Personalis.
Side by side
| Standard Biotools | Personalis | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $85M | $70M |
| Revenue growth | −6.2% | −17.7% |
| Revenue growth a year, last 5 years | −9.2% | −2.4% |
| Gross margin | 49.9% | 22.6% |
| Operating margin | −129.2% | −126.4% |
| Net margin | −87.8% | −116.7% |
| Free cash flow | −$83M | −$79M |
| Free cash flow margin | −96.8% | −114.1% |
| Return on capital | −41.9% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 8.0% | 50.6% |
| Last close | $0.61 | $14.72 |
| P/E at the last close | 1.8× | — |
| Insider trades, last 12 months | bought $11.1 million, sold $0 | bought $2.0 million, sold $8.5 million |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Standard BiotoolsPersonalis
Operating margin
Percent of revenue
Standard BiotoolsPersonalis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Standard BiotoolsPersonalis
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Standard Biotools and Personalis pages.